ArticleJournal of translational medicine2022

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.

Yali Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.